Quarterly report pursuant to Section 13 or 15(d)

8. Stockholders' Equity

8. Stockholders' Equity
3 Months Ended
Mar. 31, 2015
Equity [Abstract]  
Stockholders' Equity

On January 30, 2014, the Company announced the amendment of the licensing agreement with Baxter in which certain financial and timing aspects of the agreement were modified. As a result, the Company is entitled to receive certain amounts in development, regulatory and sales milestone payments as well as increased royalties on potential net sales. In addition, Baxter SA made a direct equity investment of $10 million in cash in exchange for 10,695,187 shares of the Company’s common stock.


On December 31, 2014, 3,244,784 shares of new common stock were granted to FDS Pharma ASS (“FDS”) in consideration for the performance of services and termination of a prior collaboration agreement between Lipoxen and FDS. FDS is a related party of SynBio, an affiliate of the Company.